臨床婦人科産科69巻1号

2015年01月発行

今月の臨床 ゲノム時代の婦人科がん診療を展望する─がんの個性に応じたpersonalizationへの道 【各論3】卵巣がん

4．明細胞腺癌の生物学的特性と分子標的治療

著者： 万代昌紀¹ 山口建² 松村謙臣² 小西郁生²

所属機関： ¹近畿大学医学部産科婦人科 ²京都大学医学研究科婦人科学産科学

ページ範囲：P.124 - P.129

●明細胞腺癌の遺伝子変化

●HNF-1βの過剰発現

●ARID1A遺伝子の変異と発現消失

●PI3K／AKT／mTOR経路の活性化

参考文献

1） Tsuchiya A, et al : Expression profiling in ovarian clear cell carcinoma : identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163 : 2503─2512, 2003

2） Okamoto T, et al : Hepatocyte nuclear factor-1β （HNF-1β）promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog, 2013［Epub ahead of print］

3） Yamaguchi K, et al : Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29 : 1741─1752, 2010

4） Yamaguchi K, et al : Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer 135 : 585─597, 2014

5） 万代昌紀，他 : 明細胞腺癌の特徴と分子標的治療．産婦の実際63 : 967─971, 2014

6） Dier U, et al : Bioenergetic analysis of ovarian cancer cell lines : profiling of histological subtypes and identification of a mitochondria-defective cell line. PLoS One 9 : e98479, 2014

7） Wiegand KC, et al : ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363 : 1532─1543, 2010

8） Jones S, et al : Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330 : 228─231, 2010

9） Katagiri A, et al : Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25 : 282─288, 2011

10） Yokoyama Y, et al : Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol 25 : 58─63, 2014

11） Reisman D, et al : The SWI／SNF complex and cancer. Oncogene 28 : 1653─1668, 2009

12） Guan B, et al : Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 106 : dju146, 2014

13） Hashiguchi Y, et al : PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101 : 71─75, 2006

14） Kuo KT, et al : Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174 : 1597─1601, 2009

15） Mabuchi S, et al : mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15 : 5404─5413, 2009

16） Tan DS, et al : Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17 : 1521─1534, 2011

17） Yap TA, et al : First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29 : 4688─4695, 2011

18） Mabuchi S, et al : Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 9 : 2411─2422, 2010

19） Wu RC, et al : Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 232 : 473─481, 2014

20） Zannoni GF, et al : Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch 465 : 193─198, 2014